Authors: Mercedes Reboredo, Haisul C. Y. Chang, Roberto Barbero, Carlos M. Rodríguez-Ortigosa, Francisco Pérez-Vizcaíno, Asunción Morán, Mónica García, Jesús M. Banales, Norberto Carreño, Félix Alegre, Ignacio Herrero, Jorge Quiroga, Jesús Prieto, Bruno Sangro
DOI: 10.1371/journal.pone.0052683
Abstract Summary
Zolmitriptan, a migraine drug, shows promise for treating portal hypertension in cirrhosis. Rat studies reveal it reduces portal pressure by decreasing blood flow, with effects enhanced when combined with propranolol. This combination therapy could benefit patients who don’t respond to standard beta-blocker treatment alone—offering new hope for managing this serious complication.
Why Brain? 🧠
Zolmitriptan lowers portal pressure in cirrhotic rats and works synergistically with propranolol, offering a potential combination therapy for portal hypertension patients who don’t respond to beta-blockers alone.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
